C12N 2750/14041
Use of virus, viral particle or viral elements as a vector
C12N2750/14041 (Use of virus, viral particle or viral elements as a vector) appears on 59 US grants and 111 published applications in this corpus.
Search patents in C12N- Granted patents
- 59
- Published applications
- 111
- Assignees
- 55
- Inventors
- 200
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 0 |
| 2003 | 0 | 1 |
| 2004 | 1 | 4 |
| 2005 | 0 | 0 |
| 2006 | 1 | 3 |
| 2007 | 2 | 1 |
| 2008 | 0 | 5 |
| 2009 | 1 | 5 |
| 2010 | 0 | 1 |
| 2011 | 1 | 1 |
| 2012 | 3 | 2 |
| 2013 | 1 | 2 |
| 2014 | 1 | 6 |
| 2015 | 2 | 4 |
| 2016 | 0 | 2 |
| 2017 | 2 | 3 |
| 2018 | 5 | 6 |
| 2019 | 2 | 3 |
| 2020 | 8 | 9 |
| 2021 | 2 | 14 |
| 2022 | 3 | 5 |
| 2023 | 8 | 9 |
| 2024 | 4 | 8 |
| 2025 | 5 | 13 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2750/14043Viral genome or elements thereof as genetic vectorIndexing code46
- C12N 2750/14042Virus or viral particle as vehicleIndexing code7
- C12N 2750/14045Special targeting system for viral vectorsIndexing code4
- C12N 2750/14044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Gene therapy for retinal disease9 Jun 2026US 12,649,007 B2Oxford University Innovation Limited
- Clinical parameters by expression of factor VIII16 Dec 2025US 12,497,632 B2Sangamo Therapeutics, Inc.
- Artificial expression constructs for selectively modulating gene expression in interneurons11 Nov 2025US 12,467,064 B2Allen Institute
- Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy5 Aug 2025US 12,377,170 B2Research Institute At Nationwide Children's Hospital
- An aav9 capsid variant for targeted gene transfer6 Aug 2026US 2026/0224742 A1Universitaetsklinikum Hamburg-Eppendorf
- Quantitative particle content assessment using hydrated state imaging and image analysis23 Jul 2026US 2026/0212690 A1Intelligent Virus Imaging Inc.
- Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy14 May 2026US 2026/0131032 A1Research Institute At Nationwide Children's Hospital
- Sod1 dual expression vectors and uses thereof19 Feb 2026US 2026/0049315 A1University of Massachusetts
- Aav-mediated expression using a synthetic promoter and enhancer18 Dec 2025US 2025/0381308 A1University of Iowa Research Foundation
Most cited
By later US patents
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same124US 6,759,237 B1The Trustees of the University of Pennsylvania · 2004
- Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same82US 7,105,345 B2University of Pennsylvania · 2006
- Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same77US 7,186,552 B2The Trustees of the University of Pennsylvania · 2007